Compare Eli Lilly And Co (LLY) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance

Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.

Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.

VNQ trades at $99.50, down 0.52% today, with technical indicators showing a bullish moving average trend but neutral oscillators. The ETF holds a dominant position in U.S. real estate with a low expense ratio of 0.13% (The Motley Fool, 2026-07-18). Recent news highlights strong year-to-date performance and comparisons with competing REIT ETFs.

Outlook remains positive due to sector momentum and income appeal, though risks include interest rate sensitivity and potential overvaluation signals from RSI levels. The dividend schedule provides income stability, but macroeconomic factors could pressure near-term performance.